A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

David Porter; Fiona Thompson; Tamara Berthoud; Claire Hutchings; Laura Andrews; Sumi Biswas; Ian Poulton; Eric Prieur; Simon Correa; Rosalind Rowland; Trudie Lang; Jack Williams; Sarah Gilbert; Robert Sinden; Stephen Todryk; Adrian Hill

doi:10.1016/j.vaccine.2011.03.083

A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

David Porter, Fiona Thompson, Tamara Berthoud, Claire Hutchings, Laura Andrews, Sumi Biswas, Ian Poulton, Eric Prieur, Simon Correa, Rosalind Rowland, Trudie Lang, Jack Williams, Sarah Gilbert, Robert Sinden, Stephen Todryk, Adrian Hill

Research output: Contribution to journal › Article › peer-review

47 Citations (Scopus)

Abstract

We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. The vaccines were safe but interferon-γ ELISPOT responses were low compared to other poxvirus vectors, despite targeting multiple antigens. There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene.

Original language	English
Pages (from-to)	7514-7522
Journal	Vaccine
Volume	29
Issue number	43
DOIs	https://doi.org/10.1016/j.vaccine.2011.03.083
Publication status	Published - 6 Oct 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Heterologous prime-boost
immunology

Access to Document

10.1016/j.vaccine.2011.03.083

Cite this

@article{c4eefbc695f0439795f53a324775ae21,

title = "A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine",

abstract = "We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. The vaccines were safe but interferon-γ ELISPOT responses were low compared to other poxvirus vectors, despite targeting multiple antigens. There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene.",

keywords = "Heterologous prime-boost, immunology",

author = "David Porter and Fiona Thompson and Tamara Berthoud and Claire Hutchings and Laura Andrews and Sumi Biswas and Ian Poulton and Eric Prieur and Simon Correa and Rosalind Rowland and Trudie Lang and Jack Williams and Sarah Gilbert and Robert Sinden and Stephen Todryk and Adrian Hill",

year = "2011",

month = oct,

day = "6",

doi = "10.1016/j.vaccine.2011.03.083",

language = "English",

volume = "29",

pages = "7514--7522",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "43",

}

TY - JOUR

T1 - A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

AU - Porter, David

AU - Thompson, Fiona

AU - Berthoud, Tamara

AU - Hutchings, Claire

AU - Andrews, Laura

AU - Biswas, Sumi

AU - Poulton, Ian

AU - Prieur, Eric

AU - Correa, Simon

AU - Rowland, Rosalind

AU - Lang, Trudie

AU - Williams, Jack

AU - Gilbert, Sarah

AU - Sinden, Robert

AU - Todryk, Stephen

AU - Hill, Adrian

PY - 2011/10/6

Y1 - 2011/10/6

N2 - We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. The vaccines were safe but interferon-γ ELISPOT responses were low compared to other poxvirus vectors, despite targeting multiple antigens. There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene.

AB - We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. The vaccines were safe but interferon-γ ELISPOT responses were low compared to other poxvirus vectors, despite targeting multiple antigens. There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene.

KW - Heterologous prime-boost

KW - immunology

UR - https://www.scopus.com/pages/publications/80053443026

U2 - 10.1016/j.vaccine.2011.03.083

DO - 10.1016/j.vaccine.2011.03.083

M3 - Article

SN - 0264-410X

VL - 29

SP - 7514

EP - 7522

JO - Vaccine

JF - Vaccine

IS - 43

ER -

A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this